1
3
2
↑1
↓3
—2
Evidence suggests MDMA maydecreaseDepression.
6 studies (6 claims)
Emerging evidence
Typical effective dose 125 (122.5–125) mgacross 3 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| psychedelic-assisted therapy using MDMA | Decreases - effect on depression is very uncertain | depression | Human | people with life-threatening diseases | Not specified in the abstract. | Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.cited 5× |
| MDMA-assisted psychotherapy | No effect - little effect | Beck's Depression Inventory | Human | treatment-resistant PTSD | 75 mg, 100 mg, and 125 mg of MDMA with psychotherapy. | A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis.cited 18× |
| MDMA-assisted psychotherapy | Decreases - improvement was greatest | Depression symptom on the BDI-II | Human | individuals with PTSD | 75-125 mg MDMA in two or three 8-hour sessions spaced a month apart. | MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.cited 199× |
| MDMA | Decreases - reduction | depression | Human | patients with terminal illness | Not specified | Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.cited 59× |
| Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA | Increases - has shown promise | conditions including depression and post-traumatic stress disorder | Human | — | Not mentioned | Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.cited 1× |
| MDMA-assisted therapy | No effect - supports the tolerability | anxiety and depression | Human | advanced-stage cancer | 120 mg MDMA (+ 60 mg optional supplemental dose) per session. | Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.cited 2× |
| MDMA-assisted therapy | No effect - will examine the effect | symptoms of anxiety and depression | Human | advanced-stage cancer | 120 mg MDMA (+ 60 mg optional supplemental dose) per session. | Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.cited 2× |